Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
28 déc. 2020 13h25 HE
|
Hutchison China MediTech Limited
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS...
Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference
22 déc. 2020 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief...
Chi-Med Announces US$100 Million Equity Investment by CPP Investments
17 nov. 2020 02h00 HE
|
Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG...
Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting
05 nov. 2020 04h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the...
Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences
30 oct. 2020 08h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief...
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
20 sept. 2020 08h25 HE
|
Hutchison China MediTech Limited
― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ― ― SANET-p results complement...
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
17 sept. 2020 06h45 HE
|
Hutchison China MediTech Limited
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application...
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
04 sept. 2020 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration...
Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China
03 sept. 2020 02h04 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453,...
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
24 août 2020 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of...